Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial

Simple item page
dc.contributor.authorDecloedt, Eric H
dc.contributor.authorLesosky, Maia
dc.contributor.authorMaartens, Gary
dc.contributor.authorJoska, John A
dc.date.accessioned2017-03-30T09:31:59Z
dc.date.available2017-03-30T09:31:59Z
dc.date.issued2017-02-04
dc.date.updated2017-02-04T19:06:10Z
dc.description.abstractBackground: The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination. Objective: We report on the change in estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease formula in participants who received ART including TDF and were enrolled in a 24 week randomised trial of lithium versus placebo in patients with HIV-associated neurocognitive impairment. Methods: We included HIV-infected adults with cognitive impairment established on ART for at least 6 months with a suppressed viral load attending public sector ART clinics in Cape Town, South Africa. We excluded participants with an eGFR or increase in potassium between the two arms during the 24 weeks. Conclusions: We found that 24-week treatment of HIV-infected patients with lithium and TDF did not result in increased nephrotoxicity.
dc.identifier.apacitationDecloedt, E. H., Lesosky, M., Maartens, G., & Joska, J. A. (2017). Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. http://hdl.handle.net/11427/24111en_ZA
dc.identifier.chicagocitationDecloedt, Eric H, Maia Lesosky, Gary Maartens, and John A Joska "Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial." (2017) http://hdl.handle.net/11427/24111en_ZA
dc.identifier.citationDecloedt, E. H., Lesosky, M., Maartens, G., & Joska, J. A. (2017). Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. AIDS Research and Therapy, 14(1), 6.
dc.identifier.ris TY - Journal Article AU - Decloedt, Eric H AU - Lesosky, Maia AU - Maartens, Gary AU - Joska, John A AB - Background: The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination. Objective: We report on the change in estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease formula in participants who received ART including TDF and were enrolled in a 24 week randomised trial of lithium versus placebo in patients with HIV-associated neurocognitive impairment. Methods: We included HIV-infected adults with cognitive impairment established on ART for at least 6 months with a suppressed viral load attending public sector ART clinics in Cape Town, South Africa. We excluded participants with an eGFR or increase in potassium between the two arms during the 24 weeks. Conclusions: We found that 24-week treatment of HIV-infected patients with lithium and TDF did not result in increased nephrotoxicity. DA - 2017-02-04 DB - OpenUCT DO - 10.1186/s12981-017-0134-2 DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2017 T1 - Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial TI - Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial UR - http://hdl.handle.net/11427/24111 ER - en_ZA
dc.identifier.urihttp://dx.doi.org/10.1186/s12981-017-0134-2
dc.identifier.urihttp://hdl.handle.net/11427/24111
dc.identifier.vancouvercitationDecloedt EH, Lesosky M, Maartens G, Joska JA. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. 2017; http://hdl.handle.net/11427/24111.en_ZA
dc.language.isoen
dc.publisherBioMed Central
dc.publisher.departmentDivision of Clinical Pharmacologyen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License
dc.rights.holderThe Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherSouth Africa
dc.subject.otherRandomised placebo-controlled clinical trial
dc.subject.otherHIV-associated neurocognitive impairment
dc.subject.otherHIV
dc.subject.otherLithium
dc.subject.otherPlacebo
dc.subject.otherAntiretroviral therapy
dc.subject.otherTenofovir
dc.titleRenal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Decloedt_Article_2017.pdf
Size:
879.81 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles